 |
SEAN McNICHOLAS
Senior Vice President,
Cardiovascular Products and U.S. Sales,
Global Pharmaceutical Business
Schering-Plough Corporation
Kenilworth, New Jersey
Sean McNicholas is senior vice president, Cardiovascular Products and U.S. Sales, for the Global Pharmaceutical Business of Schering-Plough Corporation.
McNicholas chairs the U.S. Executive Team charged with delivery of the U.S. sales and profit targets. In this role, he has day-to-day management responsibility for the U.S. sales group. On a global basis, McNicholas is responsible for the cardiovascular portfolio at Schering-Plough, namely INTEGRILIN, an injectable IIb/IIIa antiplatelet drug, and the cholesterol management therapies ezetimibe (ZETIA) and ezetimibe/simvastatin (VYTORIN), both part of a joint venture with Merck & Co., Inc., in Europe and the U.S. In Japan, McNicholas represents Schering-Plough with ezetimibe (ZETIA) as part of a joint venture with the Bayer Corp. In addition, McNicholas co-chairs the Cardiovascular and Metabolic Discovery and Development Team and leads commercial implementation plans for the corporation's pipeline projects. He is Schering-Plough's representative at PhRMA.
McNicholas joined Schering-Plough in 2002 as vice president, Marketing, with responsibility for Schering-Plough's allergy, respiratory and dermatological franchises. He came to Schering-Plough from SYN.X, Pharma Inc., Toronto, Canada, where he served as president and CEO. Previously, he held various sales, marketing and strategic planning positions with Eli Lilly and Pharmacia Corporation.
McNicholas holds a B.S. degree in environmental biology from Swansea University, Wales, Great Britain, and an M.S. degree in plant physiology from the University of Alberta, Canada.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
